Hepatorenal Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Hepatorenal Syndrome Market Outlook

Thelansis’s “Hepatorenal Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hepatorenal Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hepatorenal Syndrome Overview

Hepatorenal syndrome (HRS) is a multiorgan condition affecting both the kidneys and the liver, primarily observed in individuals with acute or chronic liver disease. The incidence of HRS in patients with decompensated liver disease is about 4%, with most cases being associated with conditions like alcoholic hepatitis, cirrhosis, or metastatic cancers leading to portal hypertension. The likelihood of HRS development reaches 18% at one year and 39% at five years in these patients, particularly those with hyponatremia and high plasma renin activity. Spontaneous bacterial peritonitis can contribute to HRS in one-third of cases. The key triggers for HRS include spontaneous bacterial peritonitis, large-volume ascites paracentesis without plasma expansion, and gastrointestinal bleeding. Any form of sepsis can provoke HRS in cirrhosis patients due to the release of sepsis-related vasoactive mediators, similar to those in portal hypertension. Liver transplantation is the definitive treatment offering the best long-term survival prospects. Prognosis varies for different types of HRS; Type 1 HRS is associated with poor survival, averaging less than two weeks. Type 2 HRS survival depends on the severity of the Child-Pugh class of liver disease, typically ranging from 6 to 12 months without treatment. HRS is estimated to occur in approximately 8-10% of individuals with ascites and cirrhosis.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Hepatorenal Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034